Eohilia™ (budesonide) – New orphan drug approval
February 12, 2024 - Takeda announced the FDA approval of Eohilia (budesonide), for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE).
February 12, 2024 - Takeda announced the FDA approval of Eohilia (budesonide), for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE).